600587 新华医疗
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入6,977,968-6.00%10,020,61910,011,8689,281,7699,482,199
减:营业总成本6,517,557-3.78%9,224,3419,238,9908,682,1248,934,873
    其中:营业成本5,225,990-4.46%7,409,6877,360,4806,827,7797,182,655
               财务费用21,29761.74%19,10414,40336,62963,652
               资产减值损失(29,650)186.71%(70,302)(47,478)(51,846)(20,973)
公允价值变动收益------12,536(43,356)61,123
投资收益48,282-8.32%70,82381,11849,726112,228
    其中:对联营企业和合营企业的投资收益(387)-100.82%63,14674,33262,10520,228
营业利润518,349-28.65%798,517756,953585,833720,186
利润总额518,456-28.40%795,661738,579576,094718,029
减:所得税费用74,372-17.48%103,76462,07849,179162,005
净利润444,084-29.95%691,897676,501526,914556,024
减:非控股权益9,773-42.35%28722,50426,842(470)
股东净利润434,311-29.61%691,610653,997500,072556,494

市场价值指针
每股收益 (元) *0.720-38.46%1.1401.1001.2301.370
每股派息 (元) *0.250--0.2500.5000.1500.150
每股净资产 (元) *13.0304.57%12.64415.68213.09112.092
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容